ACS chemical neuroscience molecule spotlight on valdoxen

Research output: Contribution to journalArticle

1 Scopus citations


A new and novel non-SSRI potential treatment option for major depressive disorders is Valdoxen (agomelatine) which is currently in phase III clinical studies. Valdoxen is a norepinephrine disinhibitor (NNDI) and is also an antagonist of the 5-HT2C receptor.

Original languageEnglish (US)
Pages (from-to)772-773
Number of pages2
JournalACS Chemical Neuroscience
Issue number12
Publication statusPublished - Dec 15 2010


ASJC Scopus subject areas

  • Biochemistry
  • Physiology
  • Cognitive Neuroscience
  • Cell Biology

Cite this